In other words, cure is probably the right word, just not for everybody.
Although if I were to die from it I wouldn't probably be able to call it anything.
Toxic epidermal necrolysis, a severe form of Stevens-Johnson Syndrome, has about a 30% mortality rate. I understand it to be a first world problem typically caused by taking certain strong medications. It's a severe and often deadly allergic reaction.
(I'm not going to provide links because both Wikipedia entries have disturbing photos. I've verified that I'm spelling both correctly so you can google it if you want. However, you probably would be hard pressed to find an article about either condition that didn't have similarly graphic photos.)
To clarify: epidermal means it's a skin condition. Skin conditions that kill people tend to not be pretty and the symptoms are highly visible.
"necro" -- "death"
"lysis" -- "busting open"
"epidermal" -- "skin"
"syndrome" -- "no known cause"
However, it's a little unclear why TEN is a point of comparison to Ebola, as one is a transmissible disease and one is something that happens to unlucky people typically in response to common small-molecule drugs. I guess TEN sounds like a probable side effect of antiviral immune therapy, but it's not mentioned in the article. And it seems a little tricky to separate the side effects from the disease when dealing with hemorrhagic diseases in particular
So while it is often the case that when a syndrome is initially named its cause is unknown, the two are really referring to different levels of abstraction of a disease. The syndrome is its effects, irrespective of whether we know its cause.
Edit: one usage is for a set of commonly concurrent symptoms, possibly with no known cause. Another common usage is a set of concurrent symptoms with multiple known causes (e.g. toxic shock syndrome).
Toxic epidermal necrolysis (TEN) is the most lethal on a scale of 4 related necrotic skin conditions[1]: TEN, SJS, EMMajor, EMMinor. The medical industry sees all 4 as kind of a sliding scale, similar to how burns are classified as different degrees and can be clinically distinguished but are still burns. They are categorized based on the percentage of your skin that becomes necrotic, and additionally which tissue types are affected.
My understanding is that herpes is one of the most common causes, although maybe that's only true for EMM and not TEN/SJS. For some reason, as we age, sometimes our body changes its reaction to herpes or other infections, becoming hypersensitive, resulting in one of the 4 previously mentioned necrotic skin conditions.
I'm sharing this, because even though my symptoms were literally staring the doctors in the face, it took years before a studious dermatologist figured out I had recurrent EMMajor. If you have "cankers" or "rashes" associated with your herpes outbreaks, ask your doctor about it, even if the rashes aren't painful. Recurrent EMMajor can be life-threatening without treatment[2] and can progress with further attacks.
[1]https://www.ncbi.nlm.nih.gov/pubmed/21873140
[2]https://www.nhs.uk/conditions/erythema-multiforme/ (warning: disturbing pictures)
For those bipolar folks out there, remember even lamotrigine can cause SJS (still very rare), which is why you should always ramp up the dose gradually. [2]
[1] https://www.fda.gov/drugs/drug-safety-and-availability/quest...
That's a small sample, but only an 18% mortality rate with the best available treatment, before this cure.
The 6%-figure was for a sub-population of victims who received one of the treatments early. There's probably a sub-sub-population of young-adult victims who're in good health and received early treatment who had a near-0% rate, too.
From glancing at Wikipedia's numbers, it seems that the average Ebola victim faces about 50% odds, so this'd improve that to about 29%.
But, with-or-without this treatment, people who receive care, especially early, enjoy better odds than their peers who don't.
> The monoclonal antibody cocktail produced by a company called Regeneron Pharmaceuticals had the biggest impact on lowering death rates, down to 29 percent, while NIAID’s monoclonal antibody, called mAb114, had a mortality rate of 34 percent. The results were most striking for patients who received treatments soon after becoming sick, when their viral loads were still low—death rates dropped to 11 percent with mAb114 and just 6 percent with Regeneron’s drug, compared with 24 percent with ZMapp and 33 percent with Remdesivir.
edit: The 6% figure is population restricted to early interventions. I am uncomfortably out of my limited knowledge here, but I think that early intervention numbers are better across the board. I'd want to compare the 6% number to the control. And I don't want to see a control! It is such a good result no matter how you look at it that they wisely halted the trial.